This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
FROM ANTIBODY PAIR TO WORKING ASSAY
ELISA Development Services
Build a custom ELISA when catalog kits or existing reagents are not enough.
- Custom targets or difficult biomarkers
- Antibody pair screening
- Assay optimization
- Real sample matrix testing
Begin Inquiry
Include the target and species, sample matrix and expected concentration range, available antibodies or standards, and intended use.
Email services@bosterbio.com or call (888) 466-3604.
When Custom ELISA Development Makes Sense
Boster Bio develops custom ELISAs, from antibody pair screening and optimization through matrix testing, fit-for-purpose validation and biomarker assay support. Use this service when no catalog kit fits, existing reagents need optimization, or performance must be confirmed in real biological samples. For other assay formats, see Boster's assay services.
No Suitable Kit
Difficult biomarkers, rare species, modified proteins, or custom targets where no off-the-shelf ELISA kit meets the research goal.
Existing Reagents Need Work
Antibodies, standards, or a prototype assay that needs better sensitivity, lower background, or a stronger standard curve.
Matrix Performance Is Unclear
Assays that work in buffer but still need testing in serum, plasma, cell culture supernatant, lysate, tissue homogenate, or other samples.
Planning a Custom Assay Development Project
ELISA projects move faster, with less rework, when the scope is clear at the start.
What Helps Most Before Kickoff
- Assay requirements. Intended use, required sensitivity and timeline help define the assay format and development plan.
- Reference standards and controls. A reference standard or positive control provides a benchmark for initial feasibility testing.
- Representative samples. A few real serum, plasma, lysate, or supernatant samples let us check interference and recovery well before validation. See the sample collection guidelines for preparation and shipping.
What to Agree On Early
- Sample availability. How many samples exist, and how precious they are, decides how much testing happens in buffer versus real matrix.
- Milestones. Feasibility, screening, optimization, and validation each take bench time; milestones agreed upfront prevent rushed decisions later.
- Acceptance criteria. Defining acceptable range, precision, and recovery in advance gives the project a clear finish line instead of open-ended tuning.
None of this has to be final before the first conversation. Share what you have, and Boster Bio will flag gaps such as missing standards or an undefined matrix.
What the Service Covers
The steps that decide whether an ELISA is usable, reproducible, and transferable.
Assay Development
Assay Format Design
Sandwich or competitive format, chosen by target type, analyte, sample matrix, throughput needs, and assay goal. To measure several analytes per sample, see custom multiplex ELISA development.
Antibody Pair Screening
For sandwich assays, capture and detection antibodies are evaluated for compatibility, signal, background and native target recognition.
Condition Optimization
Coating, blocking, antibody dilution, incubation, detection, and standard curve setup.
Signal Troubleshooting
Weak signal, high background, poor dynamic range, and unstable standard curves.
Validation and Transfer Support
Matrix Performance Testing
Spike recovery, dilution linearity, parallelism and interference testing in relevant biological samples.
Analytical Evaluation
Precision, sensitivity, range, background, selectivity, and robustness, scaled to the project scope.
Protocol Finalization
Optimized working protocol, reagent recommendations, and assay setup guidance.
Documentation Support
Data summary and transfer-support documentation for RUO or customer-led IVD development workflows.
Fit-for-Purpose Validation
Not every assay needs the same rigor. We match validation depth to how the data will be used, and agree the tier before optimization begins.
Tier 1
Early Screening Assays
For hypothesis-generating work and early target screening. Initial testing assesses target detection, background and repeatability before further development.
Tier 2
Decision-Supporting Assays
For results that inform internal go/no-go decisions. Accuracy, precision, sensitivity, and linearity are evaluated against defined acceptance ranges, without the documentation load of full validation.
Tier 3
Fully Validated Assays
For projects requiring comprehensive, documented validation against agreed performance criteria. Accuracy, precision, selectivity, sensitivity, linearity, and stability are characterized and documented in a validation report.
These tiers describe project scope; acceptance criteria are agreed for each assay.
Ready to Discuss Your ELISA Assay Project?
Send your target, sample type, and current reagents. Boster Bio will review the project and recommend the next development step.
Common ELISA Development Issues
Common development challenges include reagent pairing, assay design and matrix interference. Early feasibility testing helps identify these risks.
Epitope and Antigen Mismatch
Pairs that work on recombinant antigen can fail when the native target is folded, processed, or modified differently.
Matrix Interference and Background Noise
Assays optimized only in buffer can show high background, poor recovery, or nonlinear dilution in serum, plasma, lysate, or tissue samples.
Weak Sensitivity or Narrow Range
Low-abundance targets, including many biomarkers, need careful tuning of antibody concentration, detection chemistry, standard curve range, and incubation.
Transfer and Reproducibility Risk
Assays built without attention to reagent consistency, coating conditions, SOP compatibility, or documentation can fail on transfer or repeat production.
Biomarker Assay Development
Research biomarkers are often low-abundance, structurally complex, or present only in specific disease models, so a catalog ELISA kit often does not exist. We develop research biomarker assays for these targets in research samples.
Pharmacodynamic Markers
Track how a marker responds to treatment over time in research models. These assays need reliable sensitivity across a defined range and consistent results across repeated timepoints.
Tissue Injury and Toxicity Markers
Indicate tissue injury or toxicity in research studies. Development prioritizes selectivity and reliable quantification at low concentrations.
Subgroup Markers
Distinguish subgroups within a research study. These assays must perform consistently across the study's sample types, so matrix testing starts early.
Biomarker projects often start with antibody pair screening, or with custom antibody and antigen development, before optimization begins.
Development Process
Each phase ends at a checkpoint, so weak designs and technical risks surface before the project moves downstream.
-
Phase 1: Feasibility and Risk Review
Review target biology, species, sample matrix, expected concentration range, available reagents, intended use, and technical risks to assay performance.
Checkpoint: Confirm assay format, reagent needs, validation tier, and a go/no-go decision before committing further resources.
-
Phase 2: Antibody Pair Screening
For sandwich assays, evaluate capture and detection candidates for signal, background, epitope compatibility and native target recognition.
Checkpoint: Select a lead pair, or recommend antibody pair development or custom antigen development if no candidate works.
-
Phase 3: Assay Optimization
Optimize coating concentration, blocking, antibody dilution, incubation, detection, and standard curve setup.
Checkpoint: Advance when signal-to-noise, background, and preliminary range meet project targets.
-
Phase 4: Matrix Testing and Fit-for-Purpose Validation
Evaluate recovery, dilution linearity, precision, sensitivity, selectivity, range, and matrix interference at the agreed validation tier.
Checkpoint: Confirm performance meets the acceptance criteria set during planning.
-
Phase 5: Protocol and Documentation Delivery
Deliver the optimized protocol and documentation; follow-up support as agreed in the quote.
Typical Deliverables
Deliverables depend on project scope and are confirmed at quote.
| Project Area | Typical Output |
|---|---|
| Planning | Assay requirements review, reagent and matrix gap check, and agreed milestones with acceptance criteria. |
| Feasibility | Target review, reagent assessment, assay format recommendation, and a go/no-go development plan. |
| Screening | Antibody pair screening data and lead pair recommendation. |
| Optimization | Optimized assay conditions, standard curve setup, and working protocol. |
| Validation | Matrix performance data, recovery, linearity, precision, sensitivity, selectivity, and range at the agreed tier, with a validation report for Fully Validated assays. |
| Documentation | Data summary, optimized protocol, reagent recommendations, and transfer-support documentation when requested. |
RUO and Customer-Led IVD Development Support
Boster Bio supports structured ELISA development with documentation, traceability, reagent control, and transfer considerations.
Development Support
Projects can be structured for research use or for a customer-led diagnostic development program, which the customer leads and qualifies.
Important Note
Boster Bio does not claim FDA approval, GMP certification, or clinical certification for this service. GLP and other quality requirements are confirmed for each project before quotation.
FAQs
Common questions about custom ELISA development, antibody pair screening, matrix testing, and project requirements.
Q1. What should I provide for an ELISA development quote?
The target name, species, sample matrix, expected assay format, available antibodies or standards, and intended use. Preliminary data, failed assay results, or a current protocol also help Boster Bio review the project faster.
Q2. Can Boster Bio develop an ELISA if I do not have antibodies?
Yes. Depending on the target and goal, the project can start with reagent review, antibody sourcing, or custom antibody and antigen development before assay development.
Q3. Can you optimize an existing ELISA instead of developing one from scratch?
Yes. Boster Bio can troubleshoot weak signal, high background, poor spike recovery, nonlinear dilution, narrow dynamic range, and matrix interference in an existing ELISA or prototype assay.
Q4. What sample matrices can be tested?
Common matrices include serum, plasma, cell culture supernatant, cell lysate, and tissue homogenate. Other research samples can be tested when feasible.
Q5. Do you support RUO and customer-led IVD development programs?
Yes. Boster Bio supports research and customer-led diagnostic development projects with documentation, traceability, reagent control and transfer considerations. Project-specific quality requirements are confirmed before quotation.
Q6. What are the typical deliverables of an ELISA development project?
Depending on the agreed scope: antibody pair screening data, optimized assay conditions, standard curve setup, matrix performance data, a validation summary at the agreed tier, the optimized protocol, reagent recommendations, and transfer-support documentation.
Q7. Can this service support biomarker assay development?
Yes. Research biomarkers such as pharmacodynamic, tissue injury, and subgroup markers are common candidates, especially when the target is low-abundance or no suitable kit exists. These projects often start with antibody pair screening before optimization and matrix testing.
Q8. How is the right level of validation decided for my assay?
Validation depth is agreed according to the assay’s intended use, sample matrix and required performance. More comprehensive projects include a documented validation report.